The 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which was scheduled to take place March 13 to 16, 2020, in Philadelphia, Pennsylvania, has been canceled because of concerns surrounding the novel coronavirus disease (COVID-19) outbreak.1
We will still provide coverage of what was slated to be presented at the meeting, as AAAAI has announced that the research should be shared and promoted.
Before the cancellation, AAAAI had planned to host a special session in response to COVID-19 covering topics such as Coronavirus Epidemiology: Lessons Learned Managing Emerging Infectious Pandemics, and Coronavirus Planning and Preparedness, along with a panel discussion.
Recently, the AAAAI podcast featured Mitchell H. Grayson, MD, who discussed how COVID-19 may affect patients with allergic conditions and asthma. The episode, Coronavirus Disease (COVID-19) Update: What Healthcare Professionals and Patients Need to Know, is available on the AAAAI podcast homepage.1
The theme of this year’s meeting was New Paradigms in the Management of Allergic Disease — Focus on Biologics, a medication class that has improved outcomes for patients with asthma, atopic dermatitis, and most recently, chronic rhinosinusitis, among other allergic conditions. Approximately 20% of the sessions were dedicated to the theme, including Biologic Therapy Throughout Childhood, Asthma Biologics During Pregnancy: Safety and Use, and Cost Effectiveness of Biologic Therapy.
We will be covering research on that theme, as well as Asthma, Allergens/Allergy Testing/Allergy Therapeutics, Food Allergy, Lung Diseases Other Than Asthma, and Anaphylaxis/Urticaria/Angioedema, among others.2
1. AAAAI 2020 Annual Meeting. AAAAI website. https://annualmeeting.aaaai.org/. Accessed March 6, 2020.
2. AAAAI Annual Meeting Final Program. AAAAI website. https://annualmeeting.aaaai.org/UserFiles/2020FinalProgram_Final_WEB.pdf. Accessed March 6, 2020.